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1726-4Disease activity of pregnant women with systemic lupus
erythematosusSystemic lupus erythematosus (SLE) is an autoimmune and
multisystemic disease with a significant female predominance,
particularly during the reproductive years (ratio 15:1), affecting
up to one in 1000 women of child-bearing age.1 Pregnancy is
considered a very high-risk period for women with SLE, and
therefore has been strongly discouraged in those suffering from
SLE for the most part until recent years.1 A study of 13,555
deliveries of women with SLE showed that they had a 20-fold
higher risk of maternal mortality and a higher rate than preg-
nant women without SLE of hypertension, pregestational dia-
betes mellitus, renal impairment, pulmonary hypertension,
major infection, and hematological complications, as well as
events such as bleeding, anemia, thrombocytopenia, stroke,
deep vein thrombosis, and pulmonary embolism.2 Therefore,
the management of SLE during pregnancy remains challenging
for physicians, and outcomes for both mother and baby can be
less than optimal if the disease is not managed with caution.3 In
this issue Dr. Yang has an article addressing this important
topicdpregnancy outcomes of woman with SLE in a single
institute in northern Taiwan.4 The authors studied 60 pregnan-
cies of 55 women with SLE and found that the pregnancy
outcome was strongly positively related to the remitted disease
activity of the women with SLE prior to conception and during
pregnancy; these women with SLE that was quiescent prior to
conception and during pregnancy had a longer gestation period
and a lower complication rate with pregnancy, and delivered
newborns with higher body weight than those women with
active SLE.4 Therefore, the authors emphasized the importance
of requiring women with SLE to consult with obstetricians prior
to conception, and to maintain remitted disease activity with the
help of rheumatologists before and during pregnancy. In fact,
teamwork in modern medical care has become one of the most
important issues in providing better care for diseased patients
and for improving the global health of the general population.5
We congratulate the authors on their success and also appreciate
their contribution to this field.
There is much evidence supporting the importance of SLE
quiescence prior to conception,1,3 although multivariate
analysis from Dr. Yang's report failed to identify its value.4
The risk of flare appears to be dependent on disease activ-
ity 6e12 months before becoming pregnant.1 Women with-
out active SLE during this period have a lower risk of flarex.doi.org/10.1016/j.jcma.2014.12.007
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assduring pregnancy, but women with active SLE during this
time have a higher risk of morbidity and mortality, and this
includes not only the mothers but also the fetuses and/or
newborns, suggesting that pregnancy in women with SLE
should be well planned and well prepared for in advance. In
other words, all women with SLE should achieve complete
SLE remission before they get pregnant. However, the length
of such necessary remission remains uncertain. Many earlier
reports recommended that at least 6 months of SLE quies-
cence might be required to minimize the risk of flare during
pregnancy and provide a better maternal and fetal out-
come.1,6,7 However, with the significantly increased maternal
age in modern society,8 including the SLE population, it is
not easy to wait such a long time. The average age of the
study population in Yang's study was 29.7 years, ranging
from 20 years to 43 years.4 A recent excellent review sug-
gested that 4 months of SLE quiescence may be enough to
ensure a safe pregnancy.3 However, Dr. Yang failed to
investigate the period between remission of SLE and ini-
tiation of conception in the study, and therefore could not
suggest the best interval between SLE quiescence and con-
ception, but we still found the value of Dr. Yang's article in
further suggesting that the silent disease activity of SLE prior
to conception is strongly related to uncomplicated preg-
nancy.4 In addition, remission of SLE activity during preg-
nancy was strongly associated with a longer gestation period,
and women with activated lupus activity during pregnancy
had a threefold higher risk of preterm deliveries (<37 weeks
of gestation) than did women with remission of SLE activity
during pregnancy.4
In terms of pregnancy outcome, Dr. Yang reported that
women with SLE, regardless of disease activity before and
during pregnancy, had relatively fewer gestational weeks and
their newborns had lower body weight than in the general
population (37.4 gestational weeks vs. 38.6 gestational weeks,
and 2727 g vs. 3315 g, respectively).4,9 That is to say, late
preterm labor (defined as newborns delivered at between 34
gestational weeks and 37 gestational weeks)10 is also a sub-
stantial problem for women with SLE, regardless of their
disease activity. How to manage this high-risk population
(pregnant women with SLE) is still a challenge facing obste-
tricians, rheumatologists, and pediatricians.ociation. All rights reserved.
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that we need to know, we would like to survey the studies from
the past 3 years to provide a more complete picture of best
practices. However, as shown in a recent excellent review by
Peart and Clowse,3 it is not easy or possible to conduct a
prospective, randomized clinical trial and subsequently inter-
pret the available data to guide the therapeutic recom-
mendations because of the rarity and sensitivity of pregnancies
in women with SLE. It is difficult to comment on this, but
there is no doubt that a longer stable duration prior to con-
ception might result in a better pregnancy outcome.
A limitation of Dr. Yang's study was that the assessment of
lupus activity was based on routine monitors, including urine
routine, complete blood cell counts, erythrocyte sedimentation
rate (ESR), and serum titers of C3, C4, and double-stranded
DNA, as well as urinary protein loss and clearance rate of
creatinine.4 However, during pregnancy, ESR and serumC3 and
C4 levels are usually elevated due to increased liver production.
Therefore, women with active lupus might have serum C3 and
C4 levels within the “normal range”, suggesting that relative
variation rather than absolute levels of C3 and C4 should be
taken into consideration. By contrast, a decrease of 25% in
serum C3 and C4 levels in pregnancy should be carefully
evaluated, because this may be an earlier hint of SLE flare.11
Another limitation of Dr. Yang's study was that lupus
nephritis was not considered, although it is well known that
active lupus nephritis prior to and at conception confers the
highest risk of flare during pregnancy. This risk of flare during
pregnancy still remains higher in women with lupus nephritis
in remission.12 Therefore, women with remitted lupus neph-
ritis might not be good candidates to consider as well prepared
for pregnancy, even though a longer duration of remitted lupus
nephritis was obtained prior to conception. Any woman with
SLE during the reproductive years should be managed in an
intensive manner to avoid the occurrence of lupus nephritis,
especially those women who still plan to become pregnant.Conflicts of interest
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